Chembio Diagnostics (NASDAQ:CEMI) announced Q1 results after the close yesterday that missed views,
but investors are reacting to its update on activities related to its
DPP COVID-19 IgM/IgG blood test that it recently launched. Key
developments:
Selected by Stony Brook Medicine to identify COVID-19 survivors for a convalescent plasma study.
Received a $4M purchase order from Rio de Janeiro-based Bio-Manguinhos.
It also completed a reproducibility study of its DPP HIV-Syphilis test and submitted the data to the FDA.
https://seekingalpha.com/news/3569049-chembio-up-15-on-launch-and-initial-orders-of-covidminus-19-blood-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.